The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders
Coleman PJ, McQuillan GM, Moyer LA, Lambert SB, Margolis HS. 1998. Incidence of hepatitis B virus infection in the United States, 1976–1994: estimates from the National Health and Nutrition Examination Surveys. J Infect Dis 178(4):954–9.
DeStefano F. 2002. Risk of Demyelinating Disease After Hepatitis B Vaccination: The Vaccine Safety Datalink. Presentation to Immunization Safety Review Committee.
El-Serag HB. 2001. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 5(1):87–107, vi.
Hahn AF. 1996. Experimental allergic neuritis (EAN) as a model for the immune-mediated demyelinating neuropathies. Rev Neurol (Paris) 152(5):328–32.
Halsey NA. Recommendations for Newborn and Infant Hepatitis B Vaccination: Historical Perspective. Presentation to Immunization Safety Review Committee. 2002.
Hilleman MR. 2001. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 19(15–16):1837–48.
Hjorth RN, Bonde GM, Piner E, Hartzell RW, Rorke LB, Rubin BA. 1984. Experimental neuritis induced by a mixture of neural antigens and influenza vaccines. A possible model for Guillain-Barre syndrome. J Neuroimmunol 6(1):1–8.
IOM (Institute of Medicine). 1994. Adverse Events Associated ith Childhood Vaccines: Evidence Bearing on Causality. Washington, DC: National Academy Press.
IOM. 2001a. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: National Academy Press.
IOM. 2001b. Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders. Washington, DC: National Academy Press.
IOM. 2001c. Multiple Sclerosis: Current Status and Strategies for the Future. Washington, DC: National Academy Press;
IOM. 2002. Immunization Safety Review: Multiple Immunizations and Immune Dysfunction. Washington, DC: National Academy Press.
Lee WM. 1997. Hepatitis B virus infection. N Engl J Med 337(24):1733–45.
Maddrey WC. 2000. Hepatitis B: An important public health issue. J Med Virol 61(3):362–6.
Mast E. Recent Analyses of Hepatitis B Viral Infections in Children. Presentation to Immunization Safety Review Committee. 2002.
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. 2000. Multiple sclerosis. N Engl J Med 343(13):938–52.
Sadovnick AD, Scheifele DW. 2000. School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet 355(9203):549–50.
Shaw FE Jr, Graham DJ, Guess HA, Milstien JB, Johnson JM, Schatz GC, Hadler SC, Kuritsky JN, Hiner EE, Bregman DJ, Maynard JE. 1988. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. Am J Epidemiol 127(2):337–52.
Waubant E, Stuve O. Suspected mechanisms involved in multiple sclerosis and putative role of hepatitis B vaccine in multiple sclerosis. Commissioned Background Paper for IOM Immunization Safety Review Committee. 2002.
Wise RP, Kiminyo KP, Salive ME. 1997. Hair loss after routine immunizations. JAMA 278(14):1176–8.